<DOC>
	<DOCNO>NCT01827943</DOCNO>
	<brief_summary>In absence standard treatment indication , test evaluate new drug type target therapy indication , evaluate efficacy term tumor response survival .</brief_summary>
	<brief_title>Phase II Evaluating Efficacy Temsirolimus 2 Line Therapy Patients With Advanced Bladder Cancer</brief_title>
	<detailed_description>In absence standard treatment indication , test evaluate new drug type target therapy indication , evaluate efficacy term tumor response survival . This study also search gene involve response treatment .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Men woman least 18 year age Histologically proven Bladder cancer Locally advance metastatic disease ( stage IV ) Functional status ( ECOG / OMS ) ≤ 2 Relapse firstline chemotherapy Measurable lesion ( RECIST criterion ) Absence antineoplasic treatment 4 week precede inclusion . Biological level : Neutrophil count &gt; 1,5.109/L . Platelets &gt; 100.109/L Total serum bilirubin &lt; 1.5 × ULN Clearance créatinine 40 ml/mm If liver metastasis alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 × ULN With liver alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 × ULN Signed inform consent Both woman men must agree use medically acceptable method contraception throughout study . Women childbearing potential must negative serum pregnancy test le 7 day first perfusion study . France : Patients affiliate social security program Presence metastatic brain meningeal tumor selection scanner , weither symptomatic asymptomatic Chemotherapy , immunotherapy , radiotherapy within 4 week inclusion Known hypersensitivity temsirolimus , metabolite ( sirolimus ) , polysorbate 80 excipients Previous malignancy ( except cervical carcinoma situ , basal cell carcinoma curatively treat ) incidental ( ≤ pT2 ) prostate cancer find radical cystoprostatectomy material The drug know CYP3A4/5 inhibitor inducer specifically exclude 30th day ( least 7 halveslives , accord short duration ) first perfusion throughout study . Any food know inhibit CYP3A4/5 ( example grapefruit , grapefruit juice , starfruit starfruit juice ) also purposely exclude . Autoimmune pathology , psychiatric neurological disorder Any unstable medical condition Unstable cardiac disease Severe renal failure Unstable diabetes Pregnancy Patient enrol another therapeutic clinical trial Patient unable follow comply study procedure geographical , social medical condition Patient partially totally deprive civil right</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Relapsed bladder cancer</keyword>
</DOC>